3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
8
Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Interventions
Carboplatin
13
pembrolizumab
12
Specimen Handling
9
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Capecitabine
5
Biopsy
5
Nivolumab
4
Cyclophosphamide
4
sacituzumab govitecan
3
Gemcitabine
3
Fulvestrant
3
olaparib
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Taxes
2
Letrozole
2
Epirubicin
2
Docetaxel
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
toripalimab
1
sintilimab
1
pyrotinib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
abiraterone
×
30 days
×
Clear all
No trials found.